Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Abstract
Although transcatheter arterial chemoembolization (TACE) is the standard of care for intermediate-stage hepatocellular carcinoma (HCC), this is a largely heterogeneous disease that includes a subgroup of patients who do not benefit from TACE. The treatment strategy for this subgroup of patients currently remains an unmet need in clinical practice. Here, we performed a proof-of-concept study that lenvatinib may be a more favorable treatment option over TACE as an initial treatment in intermediate-stage HCC patients with large or multinodular tumours exceeding the up-to-seven criteria. This proof-of-concept study included 642 consecutive patients with HCC initially treated with lenvatinib or conventional TACE (cTACE) between January 2006 and December 2018. Of these patients, 176 who received lenvatinib or cTACE as an initial treatment and met the eligibility criteria (unresectable, beyond the up-to-seven criteria, no prior TACE/systemic therapy, no vascular invasion, no extrahepatic spread and Child–Pugh A liver function) were selected for the study. Propensity score matching was used to adjust for patient demographics. After propensity-score matching, the outcome of 30 patients prospectively treated with lenvatinib (14 in clinical trials, one in an early access program and 15 in real world settings) and 60 patients treated with cTACE as the initial treatment was compared. The change of albumin-bilirubin (ALBI) score from baseline to the end of treatment were −2.61 to −2.61 for 30 patients in the lenvatinib group (p = 0.254) and −2.66 to −2.09 in the cTACE group (p < 0.01), respectively. The lenvatinib group showed a significantly higher objective response rate (73.3% vs. 33.3%; p < 0.001) and significantly longer median progression-free survival than the cTACE group (16.0 vs. 3.0 months; p < 0.001). Overall survival was significantly longer in the lenvatinib group than in the cTACE group (37.9 vs. 21.3 months; hazard ratio: 0.48, p < 0.01). In patients with large or multinodular intermediate-stage HCC exceeding the up-to-seven criteria with Child–Pugh A liver function, who usually do not benefit from TACE, lenvatinib provides a more favorable outcome than TACE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“those with a large intrahepatic tumour burden (such as bilobar multifocal disease) might be considered unsuitable for TACE and therefore as candidates for systemic therapies, given a lower likelihood of objective responses and a higher risk of liver injury with embolic therapies147.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [147]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“That is, giving TACE to intermediate-stage HCC patients with up-to-seven criteria out leads to a spike in the intra-tumoral concentration of VEGF, FGF or PDGF, suggesting that blockade of these receptors may prevent the effects of a surge in proangiogenic factors [39,40].”
BackgroundA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Self-citationNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“In addition, as is very well known, antiangiogenic agents play a very important role in the normalization of tumor vasculature [44] and in the enhancement of the effective, homogeneous delivery of anticancer agents (including lipiodol and gelatin sponge) into tumor tissues [45], resulting in improved responses to TACE…”
BackgroundKudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497 · cited 4×
“Of 30 lenvatinib-treated patients, 15 were treated in prospective clinical trials followed by commercially available lenvatinib after the data cut off (one from the phase II trial [26] of lenvatinib started in 2006 and 13 from the phase III REFLECT trial [15]), one patient was treated in the early access program and 1…”
BackgroundMethodResultInfluentialSelf-citationHepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415 · cited 1×
“Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide and an important health concern[1-3].”
BackgroundMarrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539 · cited 2×
“Up to now, there has been no report on the efficacy of initial treatment with lenvatinib for intermediate-stage HCC without prior TACE since it is not recommended by worldwide guidelines such as the European Association for the Study of the Liver (EASL) [5], American Association for the Study of Liver Diseases (AASLD)…”
MethodModified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329 · cited 1×
“Treatment response in both groups was evaluated by dynamic CT in accordance with modified Response Evaluation Criteria in Solid Tumor (mRECIST) [31].”
MethodOmata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171 · cited 1×
“Up to now, there has been no report on the efficacy of initial treatment with lenvatinib for intermediate-stage HCC without prior TACE since it is not recommended by worldwide guidelines such as the European Association for the Study of the Liver (EASL) [5], American Association for the Study of Liver Diseases (AASLD)…”
MethodSelf-citation
Cited by
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“[293] – 298] Based on current data, the AASLD advises against combination therapy outside of clinical trials.”
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Targeted therapy for hepatocellular carcinoma
Huang, A., Yang, X.-R., Chung, W.-Y., Dennison, A. R., & Zhou, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00264-x · Cited by 739
“0 months).(85) Lenvatinib pharmacokinetics in HCC is affected by body weight(86,87) and a sufficient dose (relative dose intensity, RDI) is required to achieve a good therapeutic effect and consequently improved outcomes and prognosis are associated with the preservation of liver function which reduces the number of p…”
BackgroundKudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., et al. (2021) · Liver Cancer · doi:10.1159/000514174 · Cited by 678
Self-citationSystemic treatment of hepatocellular carcinoma: An EASL position paper
Bruix, J., Chan, S. L., Galle, P. R., Rimassa, L., & Sangro, B. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.004 · Cited by 380
Self-citation
Metadata
- Authors
- Kudo, M., Ueshima, K., Chan, S., Minami, T., Chishina, H., Aoki, T., Takita, M., Hagiwara, S., Minami, Y., Ida, H., Takenaka, M., Sakurai, T., Watanabe, T., Morita, M., Ogawa, C., Wada, Y., Ikeda, M., Ishii, H., Izumi, N., & Nishida, N.
- Affiliations
- Kindai University (JP)
- Chinese University of Hong Kong (HK)
- Takamatsu Red Cross Hospital (JP)
- National Kyushu Medical Center (JP)
- National Cancer Center Hospital East (JP)
- Chiba Cancer Center (JP)
- Musashino Red Cross Hospital (JP)
- Corresponding author
- Kudo, Masatoshi
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-07-31
- Volume
- 11
- Issue
- 8
- Pages
- 1084
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC6721438
- OpenAlex
- W2953756046
- Cited by
- 309
- References
- 48
- Citations by year
- 2026: 16 · 2025: 34 · 2024: 43 · 2023: 56 · 2022: 62 · 2021: 59 · 2020: 35 · 2019: 2
- FWCI
- 25.19
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Eisai
- Smoking Research Foundation
- Kobayashi Foundation for Cancer Research
- SENSHIN Medical Research Foundation
- Yakult Bio-Science Foundation
- Chugai Pharmaceutical
- Japan Society for the Promotion of Science (18K07922)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- lenvatinib, hepatocellular carcinoma, intermediate-stage HCC, transarterial chemoembolization, up-to-seven criteria, initial treatment, objective response rate, progression-free survival, overall survival, albumin-bilirubin score, real-world evidence, tyrosine kinase inhibitors, unmet medical needs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study. https://app.cochat.ai/papers/10.3390/cancers11081084
- The paper
- Kudo, M., Ueshima, K., Chan, S., Minami, T., Chishina, H., Aoki, T., Takita, M., Hagiwara, S., Minami, Y., Ida, H., Takenaka, M., Sakurai, T., Watanabe, T., Morita, M., Ogawa, C., Wada, Y., Ikeda, M., Ishii, H., Izumi, N., & Nishida, N. (2019). Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study. Cancers. https://doi.org/10.3390/cancers11081084
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.